Mashaal Dhir1, Alyson A Melin, Jeffrey Douaiher, Chi Lin, Weining Ken Zhen, Shahid M Hussain, Jean-Francois H Geschwind, Maria B Majella Doyle, Ghassan K Abou-Alfa, Chandrakanth Are. 1. *Department of Surgery, Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA†Department of Surgery, Division of Surgical Oncology, University of Nebraska Medical Center, Omaha, NE‡Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE§Department of Radiology, University of Nebraska Medical Center, Omaha¶Department of Radiology, Surgery and Oncology, Johns Hopkins School of Medicine, Baltimore, MD||Department of Surgery, Division of General Surgery, Abdominal Transplantation Section, Washington University School of Medicine, St. Louis, MO**Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
Abstract
OBJECTIVE: To review the current management, outline recent advances and address controversies in the management of hepatocellular carcinoma (HCC). SUMMARY OF BACKGROUND DATA: The treatment of HCC is multidisciplinary involving hepatologists, surgeons, medical oncologists, radiation oncologists, radiologists, interventional radiologists, and other disciplines. Each of these disciplines brings its unique perspective and differing opinions that add to controversies in the management of HCC. METHODS: A focused literature review was performed to identify recent studies on the management of HCC and thereby summarize relevant information on the various therapeutic modalities and controversies involved in the treatment of HCC. RESULTS: The main treatment algorithms continue to rely on hepatic resection or transplantation with controversies involving patients harboring early stage disease and borderline hepatic function. The other treatment strategies include locoregional therapies, radiation, and systemic therapy used alone or in combination with other treatment modalities. Recent advances in locoregional therapies, radiation, and systemic therapies have provided better therapeutic options with curative intent potential for some locoregional therapies. Further refinements in combination therapies such as algorithms consisting of locoregional therapies and systemic or radiation therapies are likely to add additional options and improve survival. CONCLUSIONS: The management of HCC has witnessed significant strides with advances in existing options and introduction of several new treatment modalities of various combinations. Further refinements in these treatment options combined with enrollment in clinical trials are essential to improve the management and outcomes of patients with HCC.
OBJECTIVE: To review the current management, outline recent advances and address controversies in the management of hepatocellular carcinoma (HCC). SUMMARY OF BACKGROUND DATA: The treatment of HCC is multidisciplinary involving hepatologists, surgeons, medical oncologists, radiation oncologists, radiologists, interventional radiologists, and other disciplines. Each of these disciplines brings its unique perspective and differing opinions that add to controversies in the management of HCC. METHODS: A focused literature review was performed to identify recent studies on the management of HCC and thereby summarize relevant information on the various therapeutic modalities and controversies involved in the treatment of HCC. RESULTS: The main treatment algorithms continue to rely on hepatic resection or transplantation with controversies involving patients harboring early stage disease and borderline hepatic function. The other treatment strategies include locoregional therapies, radiation, and systemic therapy used alone or in combination with other treatment modalities. Recent advances in locoregional therapies, radiation, and systemic therapies have provided better therapeutic options with curative intent potential for some locoregional therapies. Further refinements in combination therapies such as algorithms consisting of locoregional therapies and systemic or radiation therapies are likely to add additional options and improve survival. CONCLUSIONS: The management of HCC has witnessed significant strides with advances in existing options and introduction of several new treatment modalities of various combinations. Further refinements in these treatment options combined with enrollment in clinical trials are essential to improve the management and outcomes of patients with HCC.
Authors: Theodoros Michelakos; Dimitrios Xourafas; Motaz Qadan; Rafael Pieretti-Vanmarcke; Lei Cai; Madhukar S Patel; Joel T Adler; Fermin Fontan; Usama Basit; Parsia A Vagefi; Nahel Elias; Kenneth K Tanabe; David Berger; Heidi Yeh; James F Markmann; David C Chang; Cristina R Ferrone Journal: J Gastrointest Surg Date: 2018-09-14 Impact factor: 3.452
Authors: Jian Zheng; Deborah Kuk; Mithat Gönen; Vinod P Balachandran; T Peter Kingham; Peter J Allen; Michael I D'Angelica; William R Jarnagin; Ronald P DeMatteo Journal: Ann Surg Oncol Date: 2016-12-05 Impact factor: 5.344
Authors: Felix Krenzien; Moritz Schmelzle; Benjamin Struecker; Nathanael Raschzok; Christian Benzing; Maximilian Jara; Marcus Bahra; Robert Öllinger; Igor M Sauer; Andreas Pascher; Johann Pratschke; Andreas Andreou Journal: J Gastrointest Surg Date: 2018-01-23 Impact factor: 3.452
Authors: Jian Zheng; Jayasree Chakraborty; William C Chapman; Scott Gerst; Mithat Gonen; Linda M Pak; William R Jarnagin; Ronald P DeMatteo; Richard K G Do; Amber L Simpson Journal: J Am Coll Surg Date: 2017-09-21 Impact factor: 6.113